Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bone marrow transplantation for hemoglobinopathies.

W C Mentzer1

  • 1University of California at San Francisco, USA.

Current Opinion in Hematology
|March 4, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prospects for research in hematologic disorders: sickle cell disease and thalassemia.

JAMA·2001
Same author

Bone marrow transplantation for beta-thalassemia: the University of California San Francisco experience.

Journal of pediatric hematology/oncology·2000
Same author

Impact of bone marrow transplantation for symptomatic sickle cell disease: an interim report. Multicenter investigation of bone marrow transplantation for sickle cell disease.

Blood·2000
Same author

Stomatocytosis is absent in "stomatin"-deficient murine red blood cells.

Blood·1999
Same author

Elevated resting energy expenditure in adolescents with sickle cell anemia.

Journal of the American Dietetic Association·1999
Same author

Collaborative multicenter investigation of marrow transplantation for sickle cell disease: current results and future directions.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation·1998
Same journal

Dynamic myeloid suppressor states in cancer and inflammation and their therapeutic potential.

Current opinion in hematology·2026
Same journal

Factor XIa inhibition for the prevention of thrombosis: mechanism, clinical trial signals, and indication-specific positioning.

Current opinion in hematology·2026
Same journal

Nutrition as a regulator of hematopoietic stem cell biology and transplantation.

Current opinion in hematology·2026
Same journal

From biomimicry to clinical actionability: rethinking high-shear thrombosis as a mechanobiological system.

Current opinion in hematology·2026
Same journal

Bidirectional relationship between metabolic and thrombotic disease mechanisms.

Current opinion in hematology·2026
Same journal

The dual role of the brain-derived neurotrophic factor as a regulator of hemostasis and thrombotic risk.

Current opinion in hematology·2026
See all related articles

Allogeneic matched sibling bone marrow transplants offer high long-term survival for hemoglobinopathy patients. Research is ongoing to reduce transplant risks and expand donor options for better patient outcomes.

Area of Science:

  • Hematology
  • Transplantation Immunology
  • Genetic Blood Disorders

Background:

  • Hemoglobinopathies, like sickle cell disease and thalassemia, cause significant morbidity and mortality.
  • Allogeneic matched sibling bone marrow transplantation is a curative option but limited by donor availability and procedure risks.
  • Early intervention before organ damage improves transplant success rates.

Purpose of the Study:

  • To evaluate the efficacy and safety of allogeneic matched sibling bone marrow transplantation in hemoglobinopathy patients.
  • To explore novel, less toxic conditioning regimens for bone marrow transplantation.
  • To address the challenge of expanding the donor pool for wider patient access.

Main Methods:

  • Analysis of long-term outcomes in hemoglobinopathy patients undergoing allogeneic matched sibling bone marrow transplantation.

Related Experiment Videos

  • Investigation of nonmyeloablative conditioning regimens to reduce transplant-related toxicity.
  • Review of advancements in human leukocyte antigen (HLA) typing for unrelated donor matching.

    • Main Results:

    • Long-term, disease-free survival exceeds 90% in patients treated before organ damage.
    • Transplant-associated mortality is 5% or less with current matched sibling protocols.
    • Nonmyeloablative conditioning shows potential for further reducing procedure-related mortality.

    Conclusions:

    • Allogeneic matched sibling bone marrow transplantation is a highly effective treatment for hemoglobinopathy when performed early.
    • Ongoing research into reduced-toxicity conditioning and improved HLA-typing is crucial for expanding treatment accessibility and improving patient survival.
    • Further development is needed to overcome donor limitations and enhance transplant outcomes for a broader patient population.